Global Microbiome Therapeutics Market Report and Forecast 2024-2032

Global Microbiome Therapeutics Market Outlook

The global microbiome therapeutics market size has reached a value of more than USD 328.72 million in 2023. The market is expected to grow at a CAGR of 43.60% between 2024 and 2032, reaching a value of USD 8535.09 million by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Global Microbiome Therapeutics Market Trends

A microbiome is a group of microorganisms living in a certain environment, and in the case of humans, this term is used for microorganisms that live in or on a body part, such as the skin or gastrointestinal tract. Microbiomes are helpful in digestion, regulating the immune system, and production of essential nutrients for blood coagulation.

Microbiome therapeutics are designed to alter the gut microbiome using additives, subtractive, or modulator therapy, in addition to engineered microbes, antibiotics, and other microbes to treat human disorders.

Rising Prevalence of Sedentary Lifestyle

People are increasingly adopting a sedentary lifestyle and busy work life, which has increased the prevalence of disorders due to lack of physical activities and lack of priority for physical well-being.

Growing Cases of Obesity

Due to the busy lifestyles of people and rapid urbanisation, people are shifting more and more towards packaged and junk food, which has led to a rise in obesity cases globally. The demand for microbiome therapeutics market is significantly driven by the rising cases of obesity.

Increasing Research and Development on Human Microbiome Therapeutics

Many microbiome-based product manufacturing companies have increased their focus on the development of therapeutics drugs with studies proving that the right combination of microbes with or without treatment processes can be beneficial in treating various disorders.

Global Microbiome Therapeutics Market Opportunities

Increasing Awareness for Microbiome Therapeutics as an Alternative Treatment

Growing research and developments on microbiome therapeutics and advertisement efforts have propelled the general awareness among people around the world, providing greater opportunities for the market.

Rising Collaborative Efforts

Public and private organisations are increasing their efforts for strategic collaborations and partnerships to launch new and innovative products.

Stringent Government Policies to Obstruct the Development of the Market

The regulatory requirements by current food and drug regulatory authorities are not customised for biotherapeutic products. Although regulatory organisations have authorised multiple dietary supplements that have probiotics, these products cannot be distributed for curing, mitigating, or for treatment and prevention of any diseases.

However, the authorities are planning changes in their ways of categorising probiotics, and this might prove to be extremely beneficial to the market expansion.

Global Microbiome Therapeutics Market Analysis

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on type, the market can be segmented into faecal microbial transplants and drugs. Based on the application, it can be bifurcated into inflammatory bowel movement, diabetes, Crohn's disease, and clostridium difficile infection, among others. The regional markets can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global microbiome therapeutics market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans.

• Seres Therapeutics

• Rebiotix, Inc

• Enterome Bioscience

• MaaT Pharma

• Vedanta Biosciences, Inc.

• AOBiome LLC

• Others

Global Microbiome Therapeutics Market Types

Based on type, the market segments include faecal microbiota therapy (FMT) and drugs. Among these segments, faecal microbial transplantation, also known as stool transplantation or bacteriotherapy, has held a major share in the market. It is a procedure where healthy stool or faecal matter is collected from a healthy donor and placed in the patient’s gastrointestinal tract.

This segment is expected to further develop with increasing research and development for other therapeutic applications of FMT.

The drugs segment is expected to develop at a rapid rate during the forecast period due to increasing efforts for the development of advanced and novel drugs.

Global Microbiome Therapeutics Market Applications

Based on application, the market divisions include inflammatory bowel movement, diabetes, Crohn’s disease, and clostridium difficile infection, among others.

The clostridium difficile infection is the inflammation of the colon, which is caused by the bacteria known as clostridium difficile. This infection causes diarrhoea and colitis and results in the disruption of normal and healthy bacteria in the colon.

This segment is expected to experience significant growth due to the increasing use of faecal microbiota transplants (FMT) in the treatment of Clostridium difficile.

Crohn’s disease is a type of bowel inflammatory disease that affects the lining of a human’s digestive tract. This disease can cause abdominal pain, diarrhoea, weight loss, and anaemia. This segment is expected to go through an extensive growth with the use faecal microbiota transplantation for treatment.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

Seres Therapeutics is an American-based clinical-stage therapeutics company, which was founded in 2010. Their focus lies in the development of therapeutic products and novel drugs for the treatment of diseases by targeting the human microbiome.

Rebiotix, Inc. is a biotechnology company working around clinical-stage procedures and products, and it is based in the United States and founded in 2011. The company focuses on biotechnology research for the development of microbiome-based therapeutics including human microbiome, microbiota restoration therapy, and clostridioides difficile infection. The Rebiotix company is a part of the Ferring Pharmaceuticals company.

Enterome Bioscience is a clinical-stage biopharmaceutical company specialising in immune-oncology, auto-immunity, inflammatory bowel diseases, microbiomes, metagenomics, and immunotherapies. Their company is headquartered in France, and it was founded in 2011. They have developed highly promising products, focusing on cancer and auto-immune diseases including OncoMimics and EndoMimics.

Other market players include MaaT Pharma, Vedanta Biosciences, Inc., and ABiome LLC, among others.

Key Highlights of the Report